|
GENERIC
|
Brimonidine tartrate 0.2% | Timolol maleate 0.5%
|
|
INDICATIONS
|
Reduction of elevated intraocular pressure (IOP)
|
|
MECHANISM OF ACTION
|
Reduce aqueous production and increase outflow
|
|
MICROBIOLOGY
|
Relatively selective alpha-2 adrenergic receptor agonist with a peak ocular hypotensive effect occurring at two hours post-dosing. Fluorophotometric studies in animals and humans suggest that brimonidine tartrate has a dual mechanism of action by reducing aqueous humor production and increasing uveoscleral outflow. The predominant mechanism of ocular hypotensive action of topical beta-adrenergic blocking agents is likely due to a reduction in aqueous humor production.
|
|
CONTRAINDICATIONS & WARNINGS
|
Contraindicated in patients with Asthma, COPD, sinus bradycardia, AV block, cardiac failure, cardiogenic shock, neonates and infants, hypersensitivity reactions
|
|
PEDIATRIC USE
|
Contraindicated under age 2. The safety and effectiveness of COMBIGAN® have been established in the age groups 2 – 16 years of age.
|
|
PREGNANCY
|
Pregnancy category C | There are no adequate and well-controlled studies in pregnant women; however, in animal studies, brimonidine crossed the placenta and entered into the fetal circulation to a limited extent.
|
